Scroll Top
Unfolding The Next Generation Of Allosteric Small Molecule Therapies To Meet Patient Needs
Combining physics-based methods with artificial intelligence, Gain is developing best-in-class small molecules for disorders with high unmet medical need.
Gain Therapeutics Inc.
Lead Program
Lead Program

Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.

OUR DRUG DISCOVERY PLATFORM MAGELLAN™

By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.

Our Drug Discovery Platform Magellan™
Allosteric Protein Regulation
ALLOSTERIC PROTEIN REGULATION

Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.

Corporate Presentation
January 2025
Corporate Presentation